Valion Bio (VBIO) Income from Continuing Operations (2021 - 2025)

Valion Bio has reported Income from Continuing Operations for 5 years, with the latest figure at -$2.5 million in Q3 2025.

• On a quarterly basis, Income from Continuing Operations fell 73.24% year-over-year to -$2.5 million in Q3 2025; TTM through Sep 2025 was -$7.4 million, a 14.19% decrease from a year earlier, with the FY2024 full-year figure at -$5.7 million, up 31.33% from the prior year.
• Income from Continuing Operations was -$2.5 million for Q3 2025 at Valion Bio, down from -$1.9 million in the prior quarter.
• The five-year high for Income from Continuing Operations was -$1.2 million in Q3 2021, with the low at -$3.0 million in Q2 2022.
• Average Income from Continuing Operations over 5 years is -$1.9 million, with a median of -$1.9 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations tumbled 136.15% in 2022, then soared 37.6% in 2024.
• Over 5 years, Income from Continuing Operations stood at -$2.3 million in 2021, then advanced by 1.57% to -$2.3 million in 2022, then increased by 0.53% to -$2.2 million in 2023, then soared by 33.91% to -$1.5 million in 2024, then sank by 67.16% to -$2.5 million in 2025.
• The last three Income from Continuing Operations figures came in at -$2.5 million (Q3 2025), -$1.9 million (Q2 2025), and -$1.5 million (Q1 2025), per Business Quant data.